Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
Question
Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
Direct answer
Clinical progress presentation for Licaminlimab de-risks Oculis pipeline value ahead of PREDICT-1 Phase 3 topline binary data by year-end. — bullish pressure on OCS via biotech pipeline valuation de-risking ahead of clinical trial readout.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-07
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout”, revision 1, evidence through 2026-10-07. https://marketontology.com/catalysts/2026-10-07/oculis-to-present-licaminlimab-at-eyecelerator-ahead-of-predict-1-readout-17fa5b
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| OCS | ▲Bull | 1–3 months | biotech pipeline valuation de-risking ahead of clinical trial readout | 67 |
Oculis to Present Licaminlimab at Eyecelerator Ahead of PREDICT-1 Readout
Clinical progress presentation for Licaminlimab de-risks Oculis pipeline value ahead of PREDICT-1 Phase 3 topline binary data by year-end. — bullish pressure on OCS via biotech pipeline valuation de-risking ahead of clinical trial readout.
Oculis presenting Licaminlimab at Eyecelerator on Oct 8 with PREDICT-1 topline readout expected around year-end.
- SourceOculis presenting Licaminlimab at Eyecelerator on Oct 8 with PREDICT-1 topline readout expected around year-end.
- TransmissionClinical progress presentation for Licaminlimab de-risks Oculis pipeline value ahead of PREDICT-1 Phase 3 topline binary data by year-end.
- SummaryOculis CEO will present Licaminlimab clinical progress at Eyecelerator @ AAO 2026 on October 8. The topical anti-TNF alpha candidate remains on schedule for its registrational PREDICT-1 trial readout around year-end.
- OCSDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- OCS closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- OCS price vs. pre-event level
- OCS volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day · polygon_news · 2026-10-07
Related catalysts
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-20Oculis to present Phase 2 ACUITY trial biomarker results at ACTRIMS-ECTRIMSOCS
- 2026-10-19Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye CandidateOCS
- 2026-10-19Oculis Completes PREDICT-1 Registrational Randomization in Dry Eye CandidateOCS
- 2026-10-07Oculis to Present Licaminlimab Data Ahead of Year-End Registrational ReadoutOCS
- 2026-10-07Oculis presents dry eye candidate Licaminlimab ahead of year-end Phase 3 readoutOCS
- 2026-10-07Oculis to Present Licaminlimab Data at AAO 2026 Ahead of PREDICT-1 ReadoutOCS
- 2026-10-07Oculis to Present Licaminlimab at AAO 2026 Ahead of Year-End PREDICT-1 ReadoutOCS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.